CAS: 12001-79-5; Vitamin K1

化学文摘社编号12001-79-5有关的具体化合物是氯丙酮,又称维生素K1,主要在绿叶蔬菜和一些植物油中找到,在合成血凝结和保持骨头健康所需的蛋白方面发挥着关键作用.维生素K的特征是脂溶性,允许其在有食用脂肪的情况下吸收.它对光和热十分敏感,这可能影响其稳定性.除了在凝结方面的作用外,维生素K还参与对骨骼和血液中的钙的调节.维生素K的缺陷可导致更多的出血和与骨头有关的问题.

结构式图片

MSDS等安全信息

上下游产品

甲萘醌 Menadione 58-27-5
2-Chloromethyl-3-Methyl-1,4-Naphthoquinone 31599-79-8

合成工艺路线路线简述

    Alkaline Earth Salt Of/the/ Methylsulfuric Acid置于magnesium Sulfate,Silver(L) Oxide体系中,用 乙醚 用作溶剂,以56%的收率获得维生素k
    参考文献:Doetz,Karl Heinz; Pruskil,Ingrid; Muehlemeier,Jochen,Chemische Berichte,1982,Vol. 115,# 4,P. 1278-1285
    标题:Doetz,Karl Heinz; Pruskil,Ingrid; Muehlemeier,Jochen,Chemische Berichte,1982,Vol. 115,# 4,P. 1278-1285

    海关参考信息

    专利信息


    专利号:US-12168649-B2
    优先权日:2018-08-17
    标 题 :Synthesis of chromanol and 2-methyl-1,4-naphthoquinone derivatives
    发明人:WEINGARTEN MELANIE; SIEGEL WOLFGANG; PUHL MICHAEL
    权利人:BASF SE
    摘要:The present invention relates to a process for the production of chromanol and 2-methyl-1,4-naphthoquinone derivatives, more specifically to a process for preparing a compound of the general formula (I) or (II) wherein the variables are as defined in the claims and the description.

    专利号:US-2014357576-A1
    优先权日:2013-05-31
    标题:Methods for enhancement of muscle protein synthesis
    发明人:BREUILLE DENIS; STELLINGWERFF TRENT; MOORE DANIEL RYAN; OFFORD CAVIN ELIZABETH ANN; PHILLIPS STUART MARTIN
    权利人:NESTEC SA
    摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis by enhancing myofibrillar muscle protein synthesis. The method includes administering to the individual a mixed macronutrient composition having (i) an amount of whey protein that is not capable of enhancing myofibrillar protein synthesis when ingested by itself and (ii) free leucine. The composition comprises at least about 5.0 g total leucine per dose.

    专利号:US-2014294788-A1
    优先权日:2013-03-26
    标 题 :Methods for enhancing muscle protein synthesis following concurrent training
    发明人:BAILEY DAVID MARK; ZALTAS ERIC SCOTT; MOORE DANIEL RYAN; STELLINGWERFF TRENT
    权利人:NESTEC SA
    摘要:The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training.

    专利号:US-2005085555-A1
    优先权日:1997-08-21
    标 题:Composition, synthesis and therapeutic applications of polyamines
    发明人:MURPHY MICHAEL A; MALACHOWSKI MITCHELL R
    摘要:This invention relates to a process of synthesis and composition of open chain (ring), closed ring, linear branched and or substituted polyamines, polyamine derived tyrosine phosphatase inhibitors and PPAR partial agonists/partial antagonists via a series of substitution reactions and optimizing the bioavailability and biological activities of the compounds. Polyamines prevent the toxicty of neutoxins and diabetogenic toxins including paraquat, methyphenyl pyridine radical, rotenone, diazoxide, streptozotocin and alloxan. These polyamines can be to treat neurological, cardiovascular, endocrine acquired and inherited mitochondrial DNA damage diseases and other disorders in mammalian subjects, and more specifically to the therapy of Parkinson's disease, Alzheimer's disease, Lou Gehrig's disease, Binswanger's disease, Olivopontine Cerebellar Degeneration, Lewy Body disease, Diabetes, Stroke, Atherosclerosis, Myocardial Ischemia, Cardiomyopathy, Nephropathy, Ischemia, Glaucoma, Presbycussis, Cancer, Osteoporosis, Rheumatoid Arthritis, Inflammatory Bowel Disease, Multiple Sclerosis and as Antidotes to Toxin Exposure.

    专利号:WO-2020035601-A1
    优先权日:2018-08-17
    标 题:Synthesis of chromanol and 2-methyl-1,4-naphthoquinone derivatives

    专利号:EP-3837248-B1
    优先权日:2018-08-17
    标题 :Synthesis of chromanol and 2-methyl-1,4-naphthoquinone derivatives
    杭州德立化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.dlchemical.com
    企业联系电话:0571-28006267👤
    📞杭州德立化工有限公司 ⚠️参考联系方式
    联系人:朱经理
    电话:0571-28006267

    传真:0571-28006269
    邮箱:exp@dlchemical.com
    通信地址: 西湖区古墩路387号金桂大厦
    邮编: 310012
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:西湖区古墩路387号金桂大厦
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    浙江威仕生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.vitaweishi.com
    企业联系电话:0573-88718797👤
    📞浙江威仕生物科技有限公司 ⚠️参考联系方式
    联系人:销售部
    电话:0573-88718797

    传真:0573-88718796
    邮箱:kpd@wecanbio.com
    通信地址: 浙江省桐乡市乌镇镇城东路工业园区兴康路71号
    邮编: 314501
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:浙江省桐乡市乌镇镇城东路工业园区兴康路71号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1186/1741-7015-8-13
    摘要:Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, Jin W, Kavianpour A, Yamazaki Y, Khan AM, Hossain M, Su-Myat KK, Wood PL, Krenitsky K, Takemasa I, Miyake M, Sekimoto M, Monden M, Matsubara H, Nomura F, Goodenowe DB. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Medicine. 2010 Feb 15;8(1):13. doi: 10.1186/1741-7015-8-13.
    参考文献:10.1016/j.annfar.2010.01.010
    摘要:Steib A, Marret E, Albaladejo P, Piriou V. [Perioperative care of patients taking vitamin K antagonists: register yourself!]. Ann Fr Anesth Reanim. 2010 Jan;29(1):1–2. doi: 10.1016/j.annfar.2010.01.010.
    参考文献:10.1111/j.1537-2995.2011.03237.x
    摘要:Nascimento B, Al Mahoos M, Callum J, Capone A, Pacher J, Tien H, Rizoli S. Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography. Transfusion. 2012 Jan;52(1):7–13. doi: 10.1111/j.1537-2995.2011.03237.x.
    参考文献:10.1016/j.amjmed.2011.03.013
    摘要:De Caterina R, Hylek EM. Stroke Prevention in Atrial Fibrillation: Current Status and Near-Future Directions. The American Journal of Medicine. 2011 Sep;124(9):793–9. doi: 10.1016/j.amjmed.2011.03.013.
    参考文献:10.1345/aph.1p670
    摘要:Anthony CJ, Karim S, Ackroyd-Stolarz S, Fry A, Murphy NG, Christie R, Zed PJ. Intensity of anticoagulation with warfarin and risk of adverse events in patients presenting to the emergency department. Ann Pharmacother. 2011 Jul;45(7-8):881–7. doi: 10.1345/aph.1p670.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知